CollPlant Biotechnologies Financial Ratios
NASDAQ: OPHIHealth CareIndustrial SpecialtiesUSD
3.13-0.08 (-2.49%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CollPlant Biotechnologies ratio analysis
CollPlant Biotechnologies earned a net margin of -484.6% in FY 2025, up from -3225.0% a year earlier. Gross margin was 64.8% compared with a median of 59.0% over the prior 8 years. Return on equity reached -188.9%, meaning CollPlant Biotechnologies generated -1.89 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
CollPlant Biotechnologies financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 64.8% | -215.5% | 81.8% | -33.8% | 87.2% | 51.1% | 18.9% | 66.9% | 89.6% |
| Operating margin | -484.3% | -3,349.7% | -68.5% | -5,718.1% | 0.4% | -91.2% | -329.2% | -84.7% | -1,286.6% |
| Net margin | -484.6% | -3,225.0% | -64.0% | -5,660.5% | 1.5% | -94.1% | -481.6% | -124.6% | -1,306.9% |
| Free cash flow margin | -398.4% | -2,830.3% | -33.9% | -5,007.4% | 6.9% | -79.6% | -310.4% | -40.9% | -1,100.0% |
| Return on equity (ROE) | -188.9% | -123.3% | -24.8% | -52.4% | 0.5% | -129.0% | -273.1% | -115.3% | -117.0% |
| Return on assets (ROA) | -106.5% | -88.8% | -20.6% | -44.8% | 0.5% | -53.3% | -103.8% | -71.4% | -74.8% |
| Debt / equity | — | — | — | 0.01 | 0.01 | 0.00 | 0.02 | — | 0.39 |
| Current ratio | 2.53 | 4.44 | 8.62 | 10.20 | 14.96 | 1.68 | 1.46 | 3.21 | 4.56 |
| Revenue growth | 360.4% | -95.3% | 3,565.2% | -98.1% | 154.9% | 164.8% | -53.8% | 982.9% | — |
| EPS growth | — | — | — | -7,750.0% | — | — | -255.9% | — | — |